Table 3.
Antimicrobial activity of commercial ZnO, ZnO nano, ZnO/CAT and ZnO/CA against Staphylococcus aureus
| Samples | Sample concentration (μg/mL) | Concentration of incorporated Zn2+ (μg/mL)a | S. aureus inhibition (%) |
|---|---|---|---|
| Commercial ZnO | 200 | 198 | 45.6 ± 1.3 |
| 500 | 495 | 63.5 ± 1.4 | |
| 650 | 643,5 | 100 ± 0.00 | |
| ZnO nano | 150 | 117 | 22.7 ± 1.1 |
| 200 | 156 | 58.3 ± 1.0 | |
| 250 | 195 | 100 ± 0.0 | |
| ZnO/CAT | 1000 | 102 | 4.6 ± 0.6 |
| 1250 | 127.5 | 16.6 ± 0.9 | |
| 2000 | 204 | 100 ± 0.0 | |
| ZnO/CA | 500 | 63 | 6.3 ± 0.2 |
| 750 | 94.5 | 43.8 ± 0.2 | |
| 1000 | 126 | 100 ± 0.0 |
aAverage concentration of incorporated Zn2+ as determined by atomic absorption spectrophotometry: commercial ZnO, 99%, ZnO nano, 78 mass%; ZnO/CAT, 10.2 mass%; ZnO/CA, 12.6 mass%